Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.

García-Vega, Yanelda

Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial. [electronic resource] - BMC pharmacology & toxicology Dec 2012 - 20 p. digital

Publication Type: Clinical Trial; Journal Article

2050-6511

10.1186/2050-6511-13-20 doi


Adult
Aged
Antineoplastic Agents--adverse effects
Biomarkers--blood
Chemistry, Pharmaceutical
Cuba
Drug Combinations
Drug Stability
Drug Synergism
Female
Half-Life
Humans
Injections, Intramuscular
Interferon alpha-2
Interferon-alpha--adverse effects
Interferon-gamma--adverse effects
Male
Middle Aged
Mycosis Fungoides--blood
Neopterin--agonists
Recombinant Proteins--adverse effects
Skin Neoplasms--blood